Czech Working Group for Paediatric Gastroenterology and Nutrition guidelines for diagnostics and treatment of inflammatory bowel diseases in children – 1stedition update
Authors:
J. Bronský 1; K. Beránková 1; Z. Černá 2; I. Čopová 1; D. Ďuricová 3,4; M. Durilová 5; O. Hradský 1; E. Karásková 6; K. Mitrová 1,3; J. Nevoral 1; L. Poš 5; J. Schwarz 2; P. Szitányi 7; R. Škába 5; A. Šuláková 8; J. Tuková 7
Authors‘ workplace:
Pediatrická klinika 2. LF UK a FN Motol, Praha
1; Dětská klinika LF UK a FN Plzeň
2; Klinické a výzkumné centrum pro střevní záněty ISCARE I. V. F. a. s., Praha
3; Farmakologický ústav, 1. LF UK a VFN v Praze
4; Klinika dětské chirurgie 2. LF UK a FN Motol, Praha
5; Dětská klinika LF UP a FN Olomouc
6; Klinika dětského a dorostového lékařství 1. LF UK a VFN v Praze
7; Klinika dětského lékařství LF OU a FN Ostrava
8
Published in:
Gastroent Hepatol 2017; 71(1): 11-18
Category:
doi:
https://doi.org/10.14735/amgh201711
Overview
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.
Submitted:
20.10.2016
Accepted:
30. 10. 2016
Sources
1. Ruemmele FM, Veres G, Kolho KL et al. Consensus guidelines of ECCO/ ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis 2014; 8(10): 1179– 1207. doi: 10.1016/ j.crohns.2014.04.005.
2. Keil R, Wasserbauer M, Zádorová Z et al. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis. Scand J Gastroenterol 2016; 51(9): 1062–– 1068. doi: 10.3109/ 00365521.2016.1149883.
3. Smits LJ, Derikx LA, de Jong DJ et al. Clinical outcomes following a switch from Remicade® to the biosimilar CT--P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis 2016; 10(11): 1287– 1293.
4. Farkas K, Rutka M, Golovics PA et al. Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. J Crohns Colitis 2016; 10(11): 1273– 1278.
5. Gecse KB, Lovász BD, Farkas K et al. Efficacy and Safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohns Colitis 2016; 10(2): 133– 140. doi: 10.1093/ ecco-jcc/ jjv220.
6. Sieczkowska J, Jarzębicka D, Banaszkiewicz A et al. Switching between infliximab originator and biosimilar in pae-diatric patients with inflammatory bowel disease. Preliminary observations. J Crohns Colitis 2016; 10(2): 127– 132. doi: 10.1093/ ecco-jcc/ jjv233.
7. Radin M, Sciascia S, Roccatello D et al. Infliximab biosimilars in the treatment of inflammatory bowel diseases: a systematic review. BioDrugs 2017; 31: 37. doi: 10.1007/ s40259-016-0206-1.
8. de Ridder L, Waterman M, Turner D et al. Use of biosimilars in paediatric inflammatory bowel disease: a position statement of the ESPGHAN paediatric IBD Porto Group. J Pediatr Gastroenterol Nutr 2015; 61(4): 503– 508. doi: 10.1097/ mpg.000000 0000000903.
9. Singh N, Patel M, Rabizadeh S et al. Vedolizumab use in pediatric patients with inflammatory bowel disease. Gastroenterology 2015; 148(4): S72. doi: 10.1016/ s0016-5085(15)30250-x.
10. Conrad MA et al. The use of vedolizumab for treatment of severe pediatric inflammatory bowel disease. Gastroenterology 2015; 148(4): S72.
11. Merras-Salmio L, Kolho KL. Golimumab therapy in six patients with severe pediatric onset Crohn disease. J Pediatr Gastroenterol Nutr 2016; 63(3): 344– 347. doi: 10.1097/ MPG.0000000000001165.
12. Sandborn WJ, Gasink C, Gao LL et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 2012; 367(16): 1519– 1528. doi: 10.1056/ NEJMoa1203572.
13. Cameron FL, Garrick V, Russell RK. Ustekinumab in treatment of refractory paediatric crohn disease. J Pediatr Gastroenterol Nutr 2016; 62(3): e30. doi: 10.1097/ MPG.0000000000000608.
14. Bishop C, Simon H, Suskind D et al. Ustekinumab in pediatric Crohn disease patients. J Pediatr Gastroenterol Nutr 2016; 63(3): 348– 351. doi: 10.1097/ MPG.0000000000001146.
15. Rinawi F, Rosenbach Y, Assa A et al. Ustekinumab for resistant pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2016; 62(4): e34– e35. doi: 10.1097/ MPG.00 00000000000503.
16. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18(2): 191– 198.
17. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005; 20(8): 1149– 1157.
18. Roter DL, Hall JA, Merisca R et al. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care 1998; 36(8): 1138– 1161.
19. Bernal I, Domènech E, Garcia-Planella E et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci 2006; 51(12): 2165– 2169.
20. Levine A, Turner D. Combined azithromycin and metronidazole therapy is effective in inducing remission in pediatric Crohn’s disease. J Crohns Colitis 2011; 5(3): 222– 226. doi: 10.1016/ j.crohns.2011.01.006.
21. Turner D, Levine A, Kolho KL et al. Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: a preliminary report. J Crohns Colitis 2014; 8(11): 1464– 1470.
22. Fukuda Y, Matsui T, Suzuki Y et al. Adsorptive granulocyte and monocyte apheresis for refractory Crohn’s disease: an open multicenter prospective study. J Gastroenterol 2004; 39(12): 1158– 1164.
23. Cassinotti A, Annaloro C, Ardizzone Set al. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn’s disease. Gut 2008; 57(2): 211– 217.
24. Uhlig HH, Schwerd T, Koletzko S et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology 2014; 147(5): 990– 1007. doi: 10.1053/ j.gastro.2014.07.023.
25. Miloh T, Bulut P. Primary sclerosing cholangitis during childhood and adolescence. Clinical Liver Disease 2013; 2(5): 215– 218.
26. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51(2): 237– 267. doi: 10.1016/ j.jhep.2009.04.009.
27. Kerkar N, Miloh T. Sclerosing cholangitis: pediatric perspective. Curr Gastroenterol Rep 2010; 12(3): 195– 202. doi: 10.1007/ s11894-010-0104-5.
28. Faubion WA Jr, Loftus EV, Sandborn WJet al. Pediatric "PSC-IBD": a descriptive report of associated inflammatory bowel disease among pediatric patients with psc. J Pediatr Gastroenterol Nutr 2001; 33(3): 296– 300.
29. Bajer L, Kamenář D, Sticová E et al. Idiopatický střevní zánět u pacientů s primární sklerozující cholangitidou – samostatný fenotyp IBD. Gastroent Hepatol 2014; 68(1): 24– 35.
30. Rossi G, Sciveres M, Maruzzelli L et al. Diagnosis of sclerosing cholangitis in children: blinded, comparative study of magnetic resonance versus endoscopic cholangiography. Clin Res Hepatol Gastroenterol 2013; 37(6): 596– 601. doi: 10.1016/ j.clinre. 2013.05.014.
31. Mamula P, Markowitz JE, Baldassano RN(eds). Pediatric inflammatory bowel disease. 2nd ed. New York: Springer-Verlag 2013: 592.
32. Dezsőfi A, Baumann U, Dhawan A et al. Liver biopsy in children: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr 2015; 60(3): 408– 420. doi: 10.1097/ MPG.000000 0000000632.
33. Hommes DW, Erkelens W, Ponsioen C et al. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol 2008; 42(5): 522– 526. doi: 10.1097/ MCG.0b013e3181662426.
34. Lindor KD, Kowdley KV, Luketic VA et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50(3): 808– 814. doi: 10.1002/ hep.23082.
35. Nevoral J. Praktická pediatrická gastroenterologie, hepatologie a výživa. Praha: Mladá fronta 2013: 677.
36. Dhawan A (ed). Concise pediatric and adolescent hepatology. London: Karger 2012: 264.
37. Tabibian JH, Weeding E, Jorgensen RA et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis – a pilot study. Aliment Pharmacol Ther 2013; 37(6): 604– 612. doi: 10.1111/ apt.12232.
38. Abarbanel DN, Seki SH, Davies Y et al. Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol 2013; 33(2): 397– 406. doi: 10.1007/ s10875-012-9801-1.
39. Davies YK, Cox KM, Abdullah BA et al. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 2008; 47(1): 61– 67. doi: 10.1097/ MPG.0b013e31816fee95.
40. Ibrahim SH, Lindor KD. Current management of primary sclerosing cholangitis in pediatric patients. Paediatr Drugs 2011; 13(2): 87– 95. doi: 10.2165/ 11586500-000000000-00000.
41. Rahier F, Magro F, Abreu C et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014; 8(6): 443– 468. doi: 10.1016/ j.crohns.2013.12.013.
42. Veereman-Wauters G, de Ridder L, Veres G et al. Risk of infection and prevention in pediatric patients with IBD: ESPGHAN IBD Porto Group commentary. J Pe-diatr Gastroenterol Nutr 2012. 54(6): 830––837. doi: 10.1097/ MPG.0b013e31824d 1438.
43. Zitomersky NL, Verhave M, Trenor CC3rd. Thrombosis and inflammatory bowel disease: a call for improved awareness and prevention. Inflamm Bowel Dis 2011; 17(1): 458– 470. doi: 10.1002/ ibd.21334.
44. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 2002; 22(2): 201– 210.
45. Nylund CM, Goudie A, Garza JM et al. Venous thrombotic events in hospital-ized children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2013; 56(5): 485– 491. doi: 10.1097/ MPG.0b013e3182801e43.
46. Blickstein D, Blickstein I. Oral contraception and thrombophilia. Curr Opin Obstet Gynecol 2007; 19(4): 370– 376.
47. Nguyen GC, Bernstein CN, Bitton A et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 2014; 146(3): 835– 848. doi: 10.1053/ j.gastro.2014.01.042.
Labels
Paediatric gastroenterology Gastroenterology and hepatology SurgeryArticle was published in
Gastroenterology and Hepatology
2017 Issue 1
Most read in this issue
- Skin conditions in patients with inflammatory bowel diseases
- When is celiac disease not celiac disease?
- Ginkor Fort® with ginkgo biloba extract
- Are there any changes in the surgical management of stenosing rectal cancer?